SEC Form 4 · accession 0001144204-17-002734
Synthetic Biologics, Inc. · SYN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph A. Sliman
Officer — Chief Medical Officer
Period of report
Jan 17, 2017
Accepted (ET)
Jan 18, 2017 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000894158
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $0.83 | Jan 17, 2017 | A | 188,927 | A | Jan 17, 2017 | Jan 16, 2024 | Common Stock | 188,927 | 188,927 | D |
Explanation of responses
- F1These options will vest monthly on a pro rata basis over 36 consecutive months.